Aspen Neuroscience, Inc. (NASDAQ:ASPE)
| Market Cap | 379.18M-12.4% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 29.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 596,560 |
| Open | 14.65 |
| Previous Close | 14.89 |
| Day's Range | 12.58 - 14.65 |
| 52-Week Range | 11.60 - 14.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
4 qualifying trades · 2 insiders · $38.00M bought in the last 90 days
About ASPE
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Ask Barron about ASPE
$ASPE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ASPE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ASPE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ASPE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ASPE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ASPE from public contracts
Source: USAspending.gov
ASPE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ASPE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.